Antibacterial and Antifungal Activity of Anticancer-Active Diazaphenothiazine Derivatives: Experimental Evaluation and Molecular Docking Studies
Pharmaceuticals · 20.11.2026 · 19 (11) · 1852
DOI: 10.3390/ph19111852 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 20.11.2026. Verfasst von Denis Swolana und 6 weiteren Autor:innen. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Silesia in Katowice, Poland.
Abstract (Originalsprache)
Background/Objectives: The rapid emergence of antimicrobial resistance necessitates the development of new agents with enhanced efficacy and well-characterized mechanisms of action. This issue is particularly relevant to bacterial and fungal superinfections associated with anticancer therapy. This study evaluated the antibacterial and antifungal activities (expressed as IC50) of two diazaphenothiazine derivatives with previously demonstrated anticancer properties: the parent compound, 10H-2,7-diazaphenothiazine (BM1), and its 10-(1-methyl-4-nitroimidazole) derivative (BM2).
Methods
Antimicrobial activity was evaluated against selected Gram-positive and Gram-negative bacterial strains and the fungus Candida albicans using the broth microdilution method. The study integrated biological assays with molecular docking, 150 ns molecular dynamics simulations, and in silico ADME predictions to compare the properties of two previously described diazaphenothiazine derivatives, BM1 and BM2.
Results
BM1 exhibited greater antibacterial activity than BM2, with the highest activity observed against Staphylococcus epidermidis, whereas both compounds showed comparable antifungal activity against Candida albicans. The incorporation of the nitroimidazole moiety into BM2 did not enhance antimicrobial activity, highlighting the importance of experimentally evaluating the effects of structural modifications. Molecular docking and molecular dynamics simulations involving DNA gyrase (GyrB), topoisomerase IV, and enoyl-acyl carrier protein reductase (FabI) revealed the differences in predicted binding interactions and protein–ligand complex dynamics, including the variations in structural stability and hydrogen-bonding patterns. These computational findings provide complementary insights into the observed activity profiles; however, experimental validation is required to establish the contribution of the proposed targets to antimicrobial activity.
Conclusions
Overall, this study contributes to the biological characterization of diazaphenothiazine derivatives and provides a basis for further investigations into the structural and physicochemical factors that may influence their antimicrobial properties.
Förderung
- Medical University of Silesia in Katowice, Poland
Zitieren
APA
Swolana, D., Kępa, M., Jeleń, M., Priya, Gaurav, A., Wojtyczka, R. D., & Morak-Młodawska, B. (2026). Antibacterial and Antifungal Activity of Anticancer-Active Diazaphenothiazine Derivatives: Experimental Evaluation and Molecular Docking Studies. Pharmaceuticals, 19(11), 1852. https://doi.org/10.3390/ph19111852
Vancouver
Swolana D, Kępa M, Jeleń M, Priya, Gaurav A, Wojtyczka RD, et al. Antibacterial and Antifungal Activity of Anticancer-Active Diazaphenothiazine Derivatives: Experimental Evaluation and Molecular Docking Studies. Pharmaceuticals. 2026;19(11):1852. doi:10.3390/ph19111852
BibTeX
@article{Swolana2026,
author = {Swolana, Denis and Kępa, Małgorzata and Jeleń, Małgorzata and Priya and Gaurav, Anand and Wojtyczka, Robert D. and Morak-Młodawska, Beata},
title = {Antibacterial and Antifungal Activity of Anticancer-Active Diazaphenothiazine Derivatives: Experimental Evaluation and Molecular Docking Studies},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {11},
pages = {1852},
doi = {10.3390/ph19111852}
}
EUVIMED